How Industry 4.0 Principles Will Help Drive the Adoption of Advanced Cell Therapies

The industry has come this far highly dependent on technologies and lessons learned from the biologics industry. How are those habits helping and hurting the progress of cell and gene therapy manufacturing? How can emerging concepts of continuous biomanufacturing, process analytical technologies (PAT), and automation help us rethink manufacturing strategies today, and for years to come? Learn from a panel of experts and industry veterans what the future will look like in advanced therapy manufacturing.

Chair:
Phil Vanek, Ph.D., Chief Technology Officer and Partner, Gamma Biosciences

Speakers:
Andy Lin, Ph.D., Vice President and Global Head of Individualized and Cell Therapy Development, Genentech
Damian Marshall, Ph.D., Vice President, Analytical Development, Resolution Therapeutics
Michael May, Ph.D., President and CEO, CCRM
Alison Moore, Ph.D., Chief Technical Officer, Allogene Therapeutics